Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer. Results ...
Are All Hypotheses Generated Before Data Analysis Prospective? THE PRODUCT LABEL for capecitabine first became of interest to me during the conduct of a phase I combination study that incorporated ...
During the first cycle of capecitabine development, three concomitant drugs were found to affect 5-FU clearance. [5] Paracetamol and morphine increased 5-FU clearance by 26% and 41%, respectively, and ...
These NGC dosage regimens are significantly more potent than existing FDA-approved capecitabine therapy based on a greater systemic and tumor exposure to 5-Fluorouracil (5-FU), the major metabolite of ...
SAN ANTONIO, Dec. 17 /PRNewswire/ -- Interim results of the Phase II XeNA (Xeloda in NeoAdjuvant) trial suggest that the combination of oral Xeloda(R) (capecitabine) and Taxotere(R) (docetaxel), with ...
Today, the US Food and Drug Administration approved several indications and other updates to the label of capecitabine tablets (Xeloda) under the agency's Project Renewal initiative. The goal of this ...
Certain oral chemotherapies may cause hand-foot syndrome, but reducing the dose of the drug allows it to heal, an expert told CURE®. Understanding the impact of side effects from drugs such as Xeloda ...
HANOVER, MD, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback